Ex Parte KOGAN et al - Page 5


                 Appeal No. 2000-0137                                                       Page 5                   
                 Application No.08/646,558                                                                           

                 amino acids.  That is, unless Lys, Arg, Gly, and Cys were considered to be                          
                 “aromatic or hydrophobic” amino acids, Xaa1 could never be Lys or Arg and Xaa2                      
                 could never be Gly or Cys, rendering the proviso meaningless.  This same                            
                 proviso is found in the specification.  See, e.g., page 3, lines 13-14.2                            
                        The specification confirms that Lys and Cys are considered to be                             
                 hydrophobic, and suggests that tyrosine (Tyr) and aspartic acid (Asp) are                           
                 considered hydrophobic as well.  See page 3, lines 12-13 (“Xaa2 and Xaa3 are                        
                 any hydrophobic, L-α-amino acid residue.”), page 4, lines 10-12 (“Xaa2 and Xaa3                     
                 are as defined above.  Preferably, . . . Xaa2 is . . . Lys, . . . or Asp; and Xaa3 is               
                 . . . Tyr.”), and page 11 lines 19-20 (“Xaa2 and Xaa3 are as defined above.                         
                 Preferably, . . . Xaa3 is . . . Cys.”).  The specification also states that leucine                 
                 (Leu), isoleucine (Ile), valine (Val), methionine (Met), tryptophan (Trp), and                      
                 phenylalanine (Phe) are preferred hydrophobic amino acids.  See page 3, lines                       
                 12-16 (“Xaa2 and Xaa3 are any hydrophobic, L-α-amino acid residue. . . .  In a                      
                 preferred embodiment, . . . Xaa2 is Leu, Ile, Val, . . . or Met and Xaa3 is Val, . . .              
                 Leu, Trp, or Phe.”).                                                                                


                                                                                                                     
                 the claim as a whole is not allowable.  If the claims are not allowable as written, the proper course
                 of action would be to enter a rejection of the claims under the appropriate statute.                
                 2 In the specification, Xaa1 is consistently defined as “any L- or D-α-amino acid residue.”  See,   
                 e.g., page 3, line 12, and page 44 (original claim 1).  In the claims on appeal, Xaa1 is limited to 
                 being an aromatic or hydrophobic amino acid.  When and if the definiteness issue discussed          
                 herein is resolved, the examiner should consider whether the specification provides an adequate     
                 written description of the genus of peptides defined by claim 32, especially the limitation of Xaa1 
                 to aromatic or hydrophobic amino acids.  See, e.g.,  Purdue Pharma L.P. v. Faulding, Inc., 230      
                 F.3d 1320, 1326, 56 USPQ2d 1481, 1486 (Fed. Cir. 2000). (“As Ruschig makes clear, one cannot        
                 disclose a forest in the original application, and then later pick a tree out of the forest and say 
                 ‘here is my invention.’  In order to satisfy the written description requirement, the blaze marks   
                 directing the skilled artisan to that tree must be in the originally filed disclosure.”).           





Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  12  13  Next 

Last modified: November 3, 2007